Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Results of Reevaluation Now Distributed in 4 Ways
December 20, 2004
- DIAGNOSTIC NEWS IN BRIEF
December 20, 2004
- BUSINESS NEWS IN BRIEF -1-
December 20, 2004
- BULLETIN
December 20, 2004
- Very Few Clinical Papers in Japan Suitable as Evidence: Expert
December 13, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 13, 2004
- Dainippon Stresses Need for "Critical Mass" via Merger
December 13, 2004
- Press Seminar
December 13, 2004
- BULLETIN
December 13, 2004
- OTC NEWS IN BRIEF
December 13, 2004
- Schering-Plough Expanding MR Force for New Product Launches: Mr Torii
December 13, 2004
- DIAGNOSTIC NEWS IN BRIEF
December 13, 2004
- JPMA to Amend Charter for Good Corporate Conduct
December 13, 2004
- 3 Qtrs Business Results
December 13, 2004
- BUSINESS NEWS IN BRIEF
December 13, 2004
- Semi-annual Business Results
December 13, 2004
- Semi-annual Business Results
December 13, 2004
- MEDICAL DEVICE NEWS IN BRIEF
December 13, 2004
- 8 Drugs Including PegIntron to Be Added to NHI List
December 13, 2004
- Astellas "1st Step Toward Becoming a Global Mega-pharma": Dr Aoki
December 13, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…